BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
NASDAQ:BIOX - Nasdaq - KYG1117K1141 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to BIOX. BIOX was compared to 85 industry peers in the Chemicals industry. BIOX may be in some trouble as it scores bad on both profitability and health. BIOX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BIOX had negative earnings in the past year.
In the past year BIOX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.18%, BIOX is in line with its industry, outperforming 43.53% of the companies in the same industry.
BIOX's Return On Equity of 0.47% is in line compared to the rest of the industry. BIOX outperforms 44.71% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.71%, BIOX is in line with its industry, outperforming 48.24% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BIOX is in line with the industry average of 7.01%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.18% | ||
| ROE | 0.47% | ||
| ROIC | 4.71% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
1.3 Margins
BIOX has a Profit Margin (0.33%) which is in line with its industry peers.
The Operating Margin of BIOX (9.09%) is comparable to the rest of the industry.
In the last couple of years the Operating Margin of BIOX has declined.
The Gross Margin of BIOX (40.53%) is better than 84.71% of its industry peers.
BIOX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 0.33% | ||
| GM | 40.53% |
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
Compared to 1 year ago, BIOX has about the same amount of shares outstanding.
BIOX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BIOX is higher compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of BIOX is 21.84, which is on the high side as it means it would take BIOX, 21.84 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 21.84, BIOX is in line with its industry, outperforming 47.06% of the companies in the same industry.
A Debt/Equity ratio of 0.47 indicates that BIOX is not too dependend on debt financing.
BIOX has a better Debt to Equity ratio (0.47) than 65.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 21.84 | ||
| Altman-Z | N/A |
ROIC/WACC0.53
WACC8.84%
2.3 Liquidity
BIOX has a Current Ratio of 1.27. This is a normal value and indicates that BIOX is financially healthy and should not expect problems in meeting its short term obligations.
BIOX has a worse Current ratio (1.27) than 76.47% of its industry peers.
A Quick Ratio of 0.88 indicates that BIOX may have some problems paying its short term obligations.
BIOX's Quick ratio of 0.88 is on the low side compared to the rest of the industry. BIOX is outperformed by 69.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The earnings per share for BIOX have decreased strongly by -551.72% in the last year.
Looking at the last year, BIOX shows a quite strong growth in Revenue. The Revenue has grown by 11.98% in the last year.
Measured over the past years, BIOX shows a very strong growth in Revenue. The Revenue has been growing by 23.73% on average per year.
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%
3.2 Future
The Earnings Per Share is expected to grow by 75.75% on average over the next years. This is a very strong growth
Based on estimates for the next years, BIOX will show a small growth in Revenue. The Revenue will grow by 6.62% on average per year.
EPS Next Y-284.41%
EPS Next 2Y68.89%
EPS Next 3Y144.94%
EPS Next 5Y75.75%
Revenue Next Year-19.62%
Revenue Next 2Y-7.02%
Revenue Next 3Y6.27%
Revenue Next 5Y6.62%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 27.51, the valuation of BIOX can be described as expensive.
Based on the Price/Forward Earnings ratio, BIOX is valued a bit more expensive than 65.88% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, BIOX is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.51 |
4.2 Price Multiples
BIOX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BIOX is cheaper than 65.88% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BIOX is valued a bit cheaper than the industry average as 62.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.78 | ||
| EV/EBITDA | 8.19 |
4.3 Compensation for Growth
BIOX's earnings are expected to grow with 144.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.89%
EPS Next 3Y144.94%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.63
+0.1 (+2.21%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners21.08%
Inst Owner Change8.72%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap290.35M
Analysts84
Price Target7.78 (68.03%)
Short Float %3.1%
Short Ratio4.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP11.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-594.26%
Min EPS beat(2)-1076.47%
Max EPS beat(2)-112.05%
EPS beat(4)0
Avg EPS beat(4)-321.88%
Min EPS beat(4)-1076.47%
Max EPS beat(4)-19.26%
EPS beat(8)1
Avg EPS beat(8)-34.87%
EPS beat(12)2
Avg EPS beat(12)-47%
EPS beat(16)3
Avg EPS beat(16)-49.47%
Revenue beat(2)0
Avg Revenue beat(2)-13.55%
Min Revenue beat(2)-16.91%
Max Revenue beat(2)-10.19%
Revenue beat(4)1
Avg Revenue beat(4)-6.5%
Min Revenue beat(4)-16.91%
Max Revenue beat(4)17.49%
Revenue beat(8)2
Avg Revenue beat(8)-4.43%
Revenue beat(12)6
Avg Revenue beat(12)8.19%
Revenue beat(16)9
Avg Revenue beat(16)10.74%
PT rev (1m)-3.17%
PT rev (3m)-44.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-190.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.51 | ||
| P/S | 0.66 | ||
| P/FCF | 23.78 | ||
| P/OCF | 9.04 | ||
| P/B | 0.94 | ||
| P/tB | 13.47 | ||
| EV/EBITDA | 8.19 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.17
Fwd EY3.63%
FCF(TTM)0.19
FCFY4.2%
OCF(TTM)0.51
OCFY11.07%
SpS7.04
BVpS4.94
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.18% | ||
| ROE | 0.47% | ||
| ROCE | 7.55% | ||
| ROIC | 4.71% | ||
| ROICexc | 5.07% | ||
| ROICexgc | 12.18% | ||
| OM | 9.09% | ||
| PM (TTM) | 0.33% | ||
| GM | 40.53% | ||
| FCFM | 2.77% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
ROICexc(3y)6.87%
ROICexc(5y)10.39%
ROICexgc(3y)15.77%
ROICexgc(5y)22.76%
ROCE(3y)9.78%
ROCE(5y)13.22%
ROICexcg growth 3Y-15.22%
ROICexcg growth 5Y-15.76%
ROICexc growth 3Y-21.1%
ROICexc growth 5Y-17.96%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
F-Score6
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 21.84 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 91.49% | ||
| Cap/Sales | 4.52% | ||
| Interest Coverage | 1.6 | ||
| Cash Conversion | 51.92% | ||
| Profit Quality | 832.88% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | N/A |
F-Score6
WACC8.84%
ROIC/WACC0.53
Cap/Depr(3y)107.09%
Cap/Depr(5y)127.69%
Cap/Sales(3y)4.36%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
EPS Next Y-284.41%
EPS Next 2Y68.89%
EPS Next 3Y144.94%
EPS Next 5Y75.75%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%
Revenue Next Year-19.62%
Revenue Next 2Y-7.02%
Revenue Next 3Y6.27%
Revenue Next 5Y6.62%
EBIT growth 1Y-3.48%
EBIT growth 3Y7.68%
EBIT growth 5Y7%
EBIT Next Year-13.11%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.7%
FCF growth 3YN/A
FCF growth 5Y-6.35%
OCF growth 1Y188.79%
OCF growth 3YN/A
OCF growth 5Y7.02%